Comparison with AstraZeneca Drug Hard to Ignore as ODAC Votes Down NSCLC Application from Clovis 

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase III trial will be needed to determine approvability of the Clovis Oncology Inc. agent rociletinib for the treatment of non-small cell lung cancer, the FDA Oncologic Drugs Advisory Committee recommended.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Health and Human Services Secretary Robert F. Kennedy Jr. is moving to overhaul the U.S. Preventive Services Task Force, a highly influential panel that determines which preventive services insurers must cover and guides routine medical care for millions of Americans. 
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login